Compare GSK plc (GSK) vs Iris Energy Limited (IREN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Iris Energy Limited — how do they compare? GSK plc trades at $46.66 (market cap $91.88B), while Iris Energy Limited trades at $35.02 (market cap $14.07B). The key difference: GSK plc is far larger — about 6.5× Iris Energy Limited's market cap, and GSK plc pays a 3.9% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Iris Energy Limited for 28 Days on average.
| GSK | IREN | |
|---|---|---|
Market Cap | $91.88B | $14.07B |
Volume | 7,730,529 | 54,492,460 |
Sector | Health | Technology |
52-Week High | $61.18 | $76.41 |
52-Week Low | $43.24 | $29.31 |
Typical Hold Time | 93 Days | 28 Days |
Enterprise Value | $111.88B | $16.02B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
IREN stock trades at $35.15, down 9.15% in the last 24 hours, reflecting bearish technical signals despite strong analyst buy ratings. The company reported revenue of $501.02M in 2025 with a net income of $86.94M, but recent quarterly EPS misses and a projected net loss of -$703M for 2026 highlight profitability challenges. Key developments include a $9.7 billion deal with Microsoft and a strategic pivot from Bitcoin mining to AI cloud services, positioning IREN in the high-growth AI infrastructure sector.
The outlook for IREN is mixed: significant upside exists from analyst price targets averaging $81.00, driven by AI demand and contracted revenue, but risks include execution on massive capital expenditure, intense competition, and current negative profitability. Investors face high volatility amid transformative growth ambitions versus near-term financial strain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Iris Energy Limited
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →
